Mondrian Investment Partners LTD lifted its stake in shares of GSK plc (NYSE:GSK - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,838,384 shares of the pharmaceutical company's stock after acquiring an additional 874,004 shares during the quarter. GSK accounts for 3.6% of Mondrian Investment Partners LTD's portfolio, making the stock its 2nd largest holding. Mondrian Investment Partners LTD owned 0.28% of GSK worth $205,920,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Sunbelt Securities Inc. boosted its position in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after buying an additional 302 shares during the period. Indiana Trust & Investment Management Co boosted its position in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust acquired a new position in shares of GSK in the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. lifted its position in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 522 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of GSK during the fourth quarter worth approximately $32,000. 15.74% of the stock is owned by institutional investors and hedge funds.
GSK Stock Up 1.1 %
NYSE GSK traded up $0.40 during trading on Tuesday, hitting $35.68. 3,700,537 shares of the company traded hands, compared to its average volume of 4,629,118. The company has a market capitalization of $73.61 billion, a P/E ratio of 22.44, a PEG ratio of 1.12 and a beta of 0.56. The business has a fifty day simple moving average of $37.47 and a 200 day simple moving average of $36.18. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.
GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, sell-side analysts predict that GSK plc will post 4.14 EPS for the current year.
GSK Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.41%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, February 21st. GSK's payout ratio is presently 100.63%.
Wall Street Analyst Weigh In
A number of research firms have issued reports on GSK. BNP Paribas assumed coverage on shares of GSK in a research report on Tuesday. They issued a "neutral" rating and a $35.25 target price for the company. Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Eight analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.58.
Check Out Our Latest Stock Report on GSK
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
